2-5A-antisense chimeras: Inhibitors of respiratory syncytial virus infection

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 3, 1999, Pages 307-315

  Torrence, Paul F ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLIC ACID;

ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; DRUG POTENCY; DRUG STRUCTURE; INFECTION CONTROL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS INHIBITION;

2',5'-OLIGOADENYLATE SYNTHETASE; ADENINE NUCLEOTIDES; ADENOSINE TRIPHOSPHATE; ANTISENSE ELEMENTS (GENETICS); ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DRUG DESIGN; ENDORIBONUCLEASES; ENZYME INDUCTION; HUMANS; INFANT; INTERFERONS; MODELS, MOLECULAR; OLIGORIBONUCLEOTIDES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RNA, DOUBLE-STRANDED; RNA, VIRAL; SUBSTRATE SPECIFICITY; VIRUS REPLICATION;

RESPIRATORY SYNCYTIAL VIRUS; SYNCYTIAL VIRUS;

EID: 0032993463     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Wyde PR: Respiratory syncytial virus (RSV) disease and prospects for Its control. Antiviral Res (1998) 39:63-79. •• Most recent and useful review of control strategies for RSV.
2. Update. Respiratory syncytial virus activity - United States, 1995-96 season. Morbid Mortal Wkly Rep (1995) 44:900-902.
3. New vaccine development establishing priorities. Report of the Institute of Medicine to the National Institute of Allergy and Infectious Diseases. Diseases of Importance in the United States (1985) 1:9.
4. Blanchard B: Respiratory syncytial virus infections in children. Arch Pediatr (1994) 1:738-745.
5. De Clercq E: Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections. Int J Antimicrob Ag (1996) 7:193-202. • This review especially emphasizes medicinal chemical approaches.
6. Collins PL, McIntosh K, Chanock RM: Respiratory syncytial virus. In: Fields Virology, Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (Eds). Lippincott-Raven, Philadelphia, PA (1996):1313-1351. •• Excellent review of molecular biology of RSV.
7. Carmack MA, Prober CG: Respiratory syncytial virus: Antiviral therapy. In: Antiviral Chemotherapy, Jefferies DJ, De Clercq E (Eds). John Wiley and Sons, New York (1995):357-390. • Deals with some of the short-comings of ribavirin as an anit-RSV agent.
8. Devine SM, Wingard JR: Viral infections in severely immunocompromised cancer patients. Support Care Cancer (1994) 2:355-368.
9. Schmader KE: Viral infections in the elderly. Baillieres Clin Infect Dis (1998) 5:119-136.
10. Han LL, Alexander JP, Anderson LJ: Respiratory syncytial virus pneumonia among the elderly: An assessment of disease burden. J Infect Dis (1999) 179:25-30.
11. Muder RR: Pneumonia in residents of long-term care facilitates: Epidemiology, etiology, management, and prevention. Am J Med (1998) 105:319-330.
12. Falsey AR: Respiratory syncytial virus infection in older persons. Vaccine (1998) 16:1775-1778.
13. Falsey AR, Cunningham CK, Barker WH, Kouides RW, Yuen JB, Menegus M, Weiner LB, Bonville CA, Betts RF: Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis (1995) 172:389-394.
14. Dix SP, Wingard JR: Management of viral infections in bone marrow transplant recipients. Clin Immunotherapeut (1996) 6:352-382.
15. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB: Respiratory syncytial virus-Induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (1989) 68:269-281.
16. Fujishima H, Okamoto Y, Saito I, Tsubota K: Respiratory syncytial virus and allergic conjunctivitis. J Allergy Clin Immunol (1995) 95:663-667.
17. Okamoto Y, Kudo K, Ishikawa K, Ito E, Togawa K, Saito I, Moro I, Patel JA, Ogra PL: Presence of respiratory syncytial virus genomic sequences in middle ear fluid and its relationship to expression of cytokines and cell adhesion molecules. J Infect Dis (1993) 168:1277-1281.
18. Wiselka MJ, Kent J, Cookson JB, Nicholson KG: Impact of respiratory virus-infection in patients with chronic chest disease. Epidemiol Infect (1993) 111:337-346.
19. Papadopoulos NG, Johnston SL Viruses and asthma exacerbations. Thorax (1998) 53:913-914.
20. Huang M, Bigos D, Levine M: Ventricular arrhythmia associated with respiratory syncytial viral infection. Pediatr Cardiol (1998) 19:498-500.
21. Checchia PA, Appel HJ, Callas D, Kahn S, Smith FA, Pahl E, Baden HP: Myocardiol injury in children with respiratory syncytial virus infection. Pediatrics (1998) 102(1):706.
22. O'Donnell DR, Openshaw PJM: Anaphylactic sensitization to aeroantigen during respiratory virus infection. Clin Exp Allergy (1998) 28:1501-1508.
23. Howatson AG: Viral infection and alpha interferon in SIDS. J Clin Pathol (1992) 45:25-28.
24. Johnston SL: Viruses and asthma. Allergy (1998) 53:922-932.
25. Karron RA, Ambrosino DM: Respiratory syncytial virus vaccines. Pediatr Infect Dis J (1998) 17:919-920.
26. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koemig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Yang JF: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 176:1215-1224.
27. The IMPACT-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antobody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics (1998) 102:531-537.
28. The PREVENT Study Group: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with broncopulmonary dysplasla using respiratory syncytial virus immune globulin prophylaxis. Pediatrics (1997) 99:93-99.
29. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem (1998) 67:227-264. •• Authoritative review on the mechanisms of interferons' actions.
30. Silverman RH: 2-5A-Dependent RNase L: a regulated endoribonuclease in the interferon system. In: Ribonucleases: Structure and Function. D'Alessio G, Riordan JF (Eds), Academic Press, New York (1997):515-551. •• Comprehensive review of RNase L.
31. Player MR, Torrence PF: The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther (1998) 78:55-113. •• Comprehensive review of all aspects of 2-5A including synthesis and properties of related 2′,5′-linked oligonucleotides.
32. Knight M, Cayley PJ, Silverman RH, Wreschner DH, Gilbert CS, Brown RE, Kerr IM: Radioimmune, radiobinding and HPLC analysis of 2-5A and related oligonucleotides from intact cells. Nature (1980) 288:189-192.
33. nA) in interferon-treated cells. Nucleic Acids Res (1981) 9:1571-1581.
34. 12U), induces accumulation of 2′,5′-oligoadenylates in mouse tissues. Biochem Biophys Res Commun (1986) 138:40-46.
35. Watling D, Serafinowska HT, Reese CB, Kerr IM: Analogue inhibitor of 2-5A action: effect on the interferon-mediated inhibition of encephalomyocarditis virus replication. EMBO J (1985) 4:431-436.
36. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH: A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J (1993) 12:3297-3304.
37. Zhou A, Paranjape J, Brown TL, Nie H, Naik, S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH: Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J (1997) 16:6355-6363. • Description of the biological effects of deletion of the RNase L gene.
38. Coccia EM, Romeo G, Nissim A, Marziali G, Albertini R, Affabris E, Battistini A, Fiorucci G, Orsatti R, Rossi GB Chebath J: A full-length murine 2-5A synthetase cDNA transacted in NIH-3T3 cells impairs EMCV but not VSV replication. Virology (1990) 179:228-233.
39. Chebath J, Benech P, Revel M, Vigneron M: Constitutive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus infection. Nature (1987) 330:587-588.
40. Gribaudo G, Lembo D, Cavallo G, Landolfo S, Lengyel P: Interferon action: binding of viral RNA to the 40-kilodalton 2′-5′-oligoadenylate synthetase in interferon-treated HeLa cells infected with encephalomyocarditis virus. J Virol (1991) 65:1748-1757.
41. Hovanessian AG, Wood JN: Anticellular and antiproliferative effects of pppA(2′p5′A)n. Virology (1980) 101:81-90.
42. Williams BRG, Kerr IM: Inhibition of protein synthesis by 2′-5′ linked adenine oligonucleotides in intact cells. Nature (1978) 276:88-90.
43. Floyd-Smith G, Slattery E, Lengyel P: Interferon action: RNA cleavage pattern of a (2′-5′)oligoadenylate-dependent endonuclease. Science (1981) 212:1030-1032.
44. nA-dependent ribonuclease. Nature (1981) 289:414-417.
45. Dong B, Xu L, Zhou A, Hassel BA, Lee X, Torrence PF, Silverman RH: Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J Biol Chem (1994) 269:14153-14158.
46. Nilsen TW, Weissman SG, Baglioni C: Role of 2′,5′-oligo(adenylic acid) polymerase in the degradation of ribonuclelc acid linked to double-stranded ribonucleic acid by extracts of interferon-treated cells. Biochemistry (1980) 19:5574-5579.
47. Carroll SS, Chen E, Viscount T, Geib J, Sardana MK, Gehman J, Kuo LC: Cleavage of oligoribonucleotides by the 2′,5′-oligoadenylate-dependent ribonuclease L. J Biol Chem (1996) 271:4988-4992.
48. Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A, Silverman RH: Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proc Natl Acad Sci USA (1993) 90:1300-1304. •• Germinal paper describing the concept of 2-5A-antisense.
49. Lesiak K, Khamnei S, Torrence PF: 2′,5′-Oligoadenylate antisense chimeras synthesis and properties. Bioconjug Chem (1993) 4:467-472. •• Synthesis of 2-5A-antisense molecules.
50. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BRG, Torrence PF, Silverman RH: Blockage of NF-xB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science (1994) 265:789-792. •• Description of ablation of PKR mRNA, protein, and biological function by 2-5A-antisense.
51. Maitra RK, Li G, Xiao W, Dong B, Torrence PF, Silverman RH: Catalytic cleavage of an RNA target by 2-5A-antisense and RNase L. J Biol Chem (1995) 270:15071-15075.
52. Xiao W, Li G, Player MR, Maitra RK, Waller CF, Silverman RH, Torrence PF: Nuclease-resistant composite 2′,5′-oligoadenylate-3′,5′-oligonucleotides for the targeted destruction of RNA: 2-5A-iso-antisense. J Med Chem (1998) 41:1531-1539.
53. Player MR, Maitra RK, Silverman RH, Torrence PF: Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense. Antivir Chem Chemother (1998) 9:213-319.
54. Maran A, Waller CF, Paranjape JM, Li GY, Xiao W, Zhang K, Kalaydo ME, Maitra RK, Lichtin AE, Brugger W, Torrence PF, Silverman RH: 2′,5′-oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood (1998) 92:4336-4343.
55. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK: Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene (1998) 16:3323-3330.
56. Pitkäranta A, Hovi T: Induction of interferon in human leukocyte cultures by natural pathogenic respiratory viruses. J Interferon Res (1993) 13:423-426.
57. Taylor CE, Webb MSC, Milner AD, Milner PD, Morgan LA, Scott R, Stokes GM, Swarbrick AS, Toms GL: Interferon alfa, infectious virus, and virus antigen secretion in respiratory syncytial virus infections of graded severity. Arch Dis Child (1989) 64:1656-1660.
58. Isaacs D: Production of interferon in respiratory syncytial virus bronchiolitis. Arch Dis Child (1989) 64:92-95.
59. Nakayama T, Sonoda S, Urano T, Sasaki K, Maehara N, Makino S: Detection of alpha-interferon in nasopharyngeal secretions and sera in children infected with respiratory syncytial virus. Pediatr Infect Dis J (1993) 12:925-929.
60. Roberts NJ, Hiscott J, Signs DJ: The limited role of the human interferon system response to respiratory syncytial virus challenge: Analysis and comparison to influenza virus challenge. Microb Pathog (1992) 12:409-414.
61. Merolla R, Rebert NA, Tsiviste PT, Hoffmann SP, Panuska JR: Respiratory syncytial virus-replication in human lung epithelial-cells - inhibition by tumor-necrosis-factor-alpha and interferon-beta. Am J Respir Crit Care Med (1995) 152:1358-1366.
62. Chipps BE, Sullivan WF, Portnoy JM: Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J (1993) 12:653-658.
63. Sung RYT, Yin J, Oppenheimer SJ, Tam JS, Lau J: Treatment of respiratory syncytial virus-infection with recombinant interferon alfa-2a. Arch Dis Child (1993) 69:440-442.
64. Higgins PG, Barrow GI, Tyrrell DAJ, Isaacs D, Gauci CL: The efficacy of intranasal interferon-alpha-2a in respiratory syncytial virus-infection in volunteers. Antiviral Res (1990) 14:3-10.
65. Floyd-Smith G, Denton JS: A (2′-5′) An-dependent endonuclease: tissue distribution in BALB/c mice and the effects of IFN-β-treatment and anti-IFN-α/β immunoglobulin on the levels of the enzyme. J Interferon Res (1988) 8:517-525.
66. Floyd-Smith G, Denton JS: Age-dependent changes are observed in the levels of an enzyme mediator of interferon action: a (2′-5′) A(n)-dependent endoribonuclease. Proc Soc Exp Biol Med (1988) 189:329-337.
67. Nyce JW, Metzger WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385:721-725.
68. Cirino NM, Li G, Xiao W, Torrence PF, Silverman RH: Targeting RNA decay with 2′,5′ oligoadenylate antisense in respiratory syncytial virus infected cells. Proc Natl Acad Sci USA (1997) 94:1937-1942. •• First description of inhibition of RSV by 2-5A-antisense, including evidence of specific mRNA destruction.
69. Xiao W, Li G, Lesiak K, Dong B, Silverman RH, Torrence PF: Synthesis of a 5′-thiophosphate analogue of 2-5A, a phosphatase resistant activator of the 2-5A-dependent ribonuclease. Bioorg Med Chem Lett (1994) 4:2609-2614.
70. Li G, Xiao W, Torrence PF: Synthesis and properties of second-generation 2-5A-antisense chimeras with enhanced resistance to exonucleases. J Med Chem (1997) 40:2959-2966.
71. Barnard DL, Sidwell RW, Xiao W, Player MR, Adah SA, Torrence PF: 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: Effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Res (1999) in press.
72. Player MR, Barnard DL, Torrence PF: Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc Natl Acad Sci USA (1998) 95:8874-8879. •• Description of antigenomic RNA-targeted 2-5A-antisense.
73. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261:1004-1012. • This review, although from 1993, is still relevant in its description of problems in the field of antisense.
74. Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Este JA, Reymen D, Pallansch LA, Lackman-Smith C, Wallace TL, De Clercq E, McGrath MS, Rando RF: T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 39:2426-2435.
75. Player MR, Torrence PF: Phosphorothioate oligonucleotides inhibit RNase L thereby disabling a mechanism of interferon action. Bioorg Med Chem Lett (1999) in press.
76. Torrence PF, Xiao W, Li G, Khamnei S: Development of 2′,5′-oligonucleotides as potential therapeutic agents. Curr Med Chem (1994) 1:176-191.
77. Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE: Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res (1997) 33:201-213.
78. Cramer H, Player MR, Torrence PF: Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2′-O-methylated 2-5A-antlsense oligonucleotides. Bioorg Med Chem Lett (1999) in press.
79. Verheijen JC, van der Marel GA, van Boom JH, Bayly SF, Player MR, Torrence PF: 2′, 5′-Oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L. Bioorg Med Chem Lett (1999) in press.
80. Robbins I, Mitta G, Vichier-Guerre S, Sobol R, Ubysz A, Rayner B, Lebleu B: Selective mRNA degradation by antisense oligonucleotide-2,5A chimera: involvement of RNase H and RNase L. Biochimie (19981) 80:711-720.
81. CLEVELAND CLINIC FOUNDATION (Torrence P, Silverman R, Maitra R, Lesiak K): Methods of cleaving specific strands of RNA and medical treatments thereby. US-05677289 (1997).
82. NATIONAL INSTITUTES OF HEALTH AND CLEVELAND CLINIC FOUNDATION (pending), US-08962690.